- Poster presentation
- Open Access
Mutational spectrum of WTX, WT1, CTNNB1, APC and PLCG2 genes in Wilms tumor defined by massive parallel resequencing
© Barros et al; licensee BioMed Central Ltd. 2012
- Published: 1 October 2012
- Substitution Pattern
- CTNNB1 Gene
- Library Preparation Protocol
- Missense Alteration
- Identify Point Mutation
The identification of molecular alterations that trigger Wilms tumor (WT) development is crucial to understanding the tumorigenesis of this malignancy. Currently, it is estimated that WTX and WT1 genomic losses together with CTNNB1 point mutations occur in about 30% of WTs. However, the majority of cases remain without any identified driver mutation. Results from a previous study by our group pointed to APC and PLCG2 as candidate genes altered in WT . Given the advent of modern DNA sequencing technologies, it is now feasible to evaluate large genomic regions spanning complete genes (exons and introns), allowing the description of the mutation patterns occurring in tumor cells. Thus, the aim of this study was to identify point mutations and indels in the complete sequence of APC, CTNNB1, WT1, WTX and PLCG2 genes in order to characterize both the exonic mutational spectrum and the intronic nucleotide substitution pattern.
The complete genomic regions of the selected genes, spanning a total of 430 kb, were amplified by long-range PCR in 15 WTs and 3 non-neoplasic control samples, giving a total of 60 amplicons per sample (10 kb on average). The resulting amplicons were mixed at equimolar concentrations and, for each sample, the Ion PGM library preparation protocol was performed. The libraries of the 18 bar-coded samples were combined in four sequencing pools that were individually submitted to an Ion PGM™ Sequencer run on an Ion 316™ Chip. Point mutation and indels not present in the non-neoplasic controls were selected for capillary sequencing validation. The validated alterations were screened in an independent group of 39 WT and 96 normal control samples.
For the 15 tumors and 3 normal controls, we obtained 400,000 sequences per sample on average (350× mean target coverage). At the exonic regions, four out of the four identified missense alterations were validated. None of the 37 identified indels could be confirmed, probably due to indel errors generated by the Ion PGM platform . Three of the four missense alterations were not identified in any of the 99 controls, and therefore were classified as possibly associated with WT: two at APC (Ile2541Val and Met1413Val) and one at PLCG2 (Asn946Ser). No point mutation was observed for WT1 and CTNNB1 genes. In the intronic regions, the somatic substitution pattern was evaluated by classifying the tumor's substitutions in two groups: single nucleotide polymorphisms (SNPs) (alterations also present in normal samples, dbSNP and 1000genomes) and somatic substitutions (remaining alterations). A general trend in the somatic base substitution pattern was observed, with the tumors presenting an over-representation of G:C>A:T changes (P >0.001) and a reduction of A:T>G:C changes (P >0.001) when compared to the SNP variants. Regarding the frequency of the other classes of somatic substitutions, a wide variation was observed among the different tumors.
This study provides insights into the spectrum of WT substitution mutations occurring in exonic and intronic regions of five previously associated genes, revealing a low frequency of point mutations in the coding sequence of these genes and a general over-representation of somatic G:C>A:T transitions.
- Maschietto M, de Camargo B, Brentani H, Grundy P, Sredni ST, Torres C, Mota LD, Cunha IW, Patrão DF, Costa CM, Soares FA, Brentani RR, Carraro DM: Molecular profiling of isolated histological components of Wilms tumor implicates a common role for Wnt signaling pathways in the kidney development and in the tumor. Oncology. 2008, 75: 81-91. 10.1159/000155210.View ArticlePubMedGoogle Scholar
- Loman NJ, Misra RV, Dallman TJ, Constantinidou C, Gharbia SE, Wain J, Pallen MJ: Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol. 2012, 30: 434-439. 10.1038/nbt.2198.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.